Voyager Therapeutics SVP & General Counsel Robert Hesslein to depart April 28, 2023

Voyager Therapeutics, Inc.

Robert Hesslein resigns as SVP and General Counsel effective April 28, 2023; transition period until then.
Severance includes 12 months salary continuation, prorated 2023 bonus ($180,302 target), and COBRA premium payments for 12 months.
Post-separation consulting agreement through Sept 30, 2023; unvested RSUs and stock options continue vesting during consulting term.
Hesslein signs release of claims, reaffirms confidentiality and non-solicitation obligations, and agrees to non-disparagement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert W. Hesslein

Senior Vice President and General Counsel

VYGR · Voyager Therapeutics, Inc.

Effective: 2023-04-28
Filed: February 23, 2023, 6:59 PM ET

Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert W. Hesslein resigned as Senior Vice President and General Counsel at Voyager Therapeutics, Inc..

Action: resigned
Role: Senior Vice President and General Counsel

Exact text from the filing

Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-024436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.